Theriva Biologics, Inc. (TOVX:NYSEMKT) closed at $0.208 on October 16, 2026, down 1.93% on the day. The stock trades 75.5% below its 52-week high of $0.850 and 29.9% above its 52-week low of $0.160. Over the past year, it lost 50.5%. Theriva Biologics, Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -5.24% | -13.38% | -9.61% | -49.29% | -50.50% |
In 252 trading sessions since October 16, 2025, TOVX closed higher on 73 days (29%). Its best day was April 20, 2026 (+57.69%) and its worst was October 16, 2025 (-48.81%). The stock moved 10% or more in a single session 25 times. It opened at least 5% above the previous day's high 9 times.
Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria.
Find more stocks like TOVX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.